Home - ABOUT CSTONE - Milestones
Milestones
  • Company Profile
  • Management Team
  • SAB
  • Vision & Mission
  • Milestones
  • Investor
  • Contact Us
  • 2016
    March, 2016 - CStone commences Series A-1 to A-3 rounds of financing and in aggregate raises approximately US$150 million.
    April, 2016 - CStone founded in Suzhou.
    2017
    October, 2017 - CStone Suzhou Translational Medicine Research Center established and commences operations.
    October, 2017 - China's first full-length and fully human PD-L1 monoclonal antibody (CS1001) enters Phase I clinical trial with the dosing of the first patient in China.
    2018
    May, 2018 - CStone completes Series B round of financing, raising in aggregate approximately US$262 million, the largest of Series B financing in China's biopharmaceutical sector at the time.
    June, 2018 - CStone and Blueprint Medicines Corp. (NASDAQ:BPMC) enter into an exclusive collaboration and license agreement regarding the clinical development and commercialization of avapritinib, fisogatinib, and pralsetinib, as mono-therapies or in combination with other therapies, in Greater China including Hong Kong, Macau, and Taiwan.
    June, 2018 - CStone and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) enter into an exclusive partnership and license agreement regarding the clinical development and commercialization of ivosidenib (TIBSOVO®; AG-120), as a mono-therapy or in combination with other therapies, in Greater China including Hong Kong, Macau and Taiwan.
    July, 2018 - The U.S. FDA approves TIBSOVO® (ivosidenib), a product developed by CStone's partner Agios Pharmaceuticals, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
    December, 2018 - The clinical research program for “the Category 1 new biologic drug injectable CS1001, a recombinant anti-PD-L1 fully human monoclonal antibody” receives special national support as a “13th Five-Year Plan” major new drug technology research project.
    2019
    February 26, 2019 - CStone becomes publicly listed on the Main Board of the Hong Kong Stock Exchange, stock code: 2616.
    March - May, 2019 - Four internationally renowned oncology experts appointed to CStone's Scientific Advisory Board.
    May, 2019 - CStone and Numab Therapeutics AG enter into an exclusive collaboration and license agreement regarding the clinical development and commercialization of ND021 in Mainland China, Hong Kong, Macau, Taiwan, South Korea and Singapore.
    June, 2019 - CStone submits a New Drug Application (NDA) in Taiwan for TIBSOVO® (ivosidenib), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
    June, 2019 – CStone and Bayer reach a global collaboration deal to jointly evaluate CS1001 in combination with regorafenib in key indications.
    August, 2019 – CStone signs an agreement to build its Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park.
    December, 2019 – CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial Operations, responsible for the commercialization of the Company's products.
    2020
    January, 2020 – The U.S. FDA approves AYVAKIT™ (avapritinib), a product developed by CStone's partner, Blueprint Medicines, for the treatment of adults patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
    March, 2020 – CStone submits a New Drug Application (NDA) in Taiwan for AYVAKIT™ (avapritinib), for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor (GIST).
    April, 2020- CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGRA D842V mutation.
    September,2020-CStone announces the National Medical Products Administration has accepted its New Drug Application with Priority Review Designation for Pralsetinib for the treatment of patients with RET Fusion-positive NSCLC.
    September,2020-CStone and Pfizer entered into strategic collaborations, which encompass Pfizer to invest $200 million in CStone shares and license late-stage oncology asset sugemalimab in mainland China and CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties.
    October,2020- CStone and EQRx entered global strategic partnership for two Immune Checkpoint Inhibitors: sugemalimab and CS1003.
    October,2020- CStone announced a licensing agreement with LegoChem Biosciences, Inc. , for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate. CStone obtains the exclusive global right to lead development and commercialization of LCB71 outside the Republic of Korea. This agreement adds the first ADC to our pipeline, and bolsters precision medicine franchise with a new modality.
    October,2020 - CStone announced FDA granted Breakthrough Therapy Designation to anti-PD-L1 antibody sugemalimab for the treatment of adult patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). Sugemalimab becomes the first Chinese anti-PD-L1 antibody to receive Breakthrough Therapy Designation from the U.S. FDA.
    October,2020 -Ivosidenib was included in the List of the Third Batch of Overseas New Drugs Urgently Needed in Clinical Settings released by CDE.
    November,2020-CStone announced that the National Medical Products Administration has accepted the New Drug Application for sugemalimab combined with chemotherapy for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer patients.
    2021
    February, 2021- CStone announced that anti-PD-L1 antibody sugemalimab has been granted Breakthrough Therapy Designation (BTD) by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).
    March,2021- CStone announced the National Medical Products Administration of China has approved GAVRETO® (pralsetinib) capsules for the treatment of adult patients with locally advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer after platinum-based chemotherapy.
    March,2021- CStone announced the National Medical Products Administration of China has approved AYVAKIT (avapritinib) tablets for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
    April,2021- CStone announced that the Taiwan Food and Drug Administration has approved AYVAKIT (avapritinib) tablets for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA D842V mutation.

    Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.